Target identification and validation
Leverage our technologies to identify and validate potential drug targets:
- CRISPR/Cas9
- scRNAseq
- Flow- and CyTOF-based immune profiling
- Organotypic spheroids
Our target identification efforts feed directly into our partners’ drug discovery efforts, fueling preclinical development pathways.
Related publications
Screening assay identifies new immunotherapy targets
www.ncbi.nlm.nih.gov/pubmed/30242021
3D microfluidic device models tumor microenvironment
www.ncbi.nlm.nih.gov/pubmed/29101162
Drug discovery and development
Our efforts focus on drug evaluation, responder ID, and biomarker discovery to IND submission:
- In vitro & in vivo pharmacology
- Patient-derived xenograft (PDX)
- Syngeneic models of cancer
- AstraZeneca: Collaboration to address drug-resistant lung cancer
- Janssen: Collaboration to assess next-generation immunotherapies
- Daiichi Sankyo: Collaboration to develop novel targeted therapies for lung cancer
Clinical science and correlatives
We accelerate clinical research:
- Liquid biopsy to augment precision medicine
- Immune profiling to characterize patients treated with checkpoint blockade
Related publications
Defining inflammatory microenvironment in head & neck cancer
www.ncbi.nlm.nih.gov/pubmed/28351582
“Hot” and “cold” immunophenotypes identified in lung cancer
www.ncbi.nlm.nih.gov/pubmed/27699239
Plasma NGS panel developed to identify targetable NSCLC mutations
www.ncbi.nlm.nih.gov/pubmed/26459174